Bayer Chief: Pharma’s Bad Rep Puts Europe Drug Business Model At Risk
This article was originally published in The Pink Sheet Daily
Bayer‘s Chairman Marijn Dekkers says the pharma sector’s poor public reputation and consequent loss of faith in the industry risks destroying the European drug business model.
You may also be interested in...
European Notebook: Revolutionary Change Needed for European Biotech; CHMP Releases Opinions Agenda; Growing Interest In Biosimilars
Radical change urged to help Europe compete in biotech; CHMP becomes less secretive over its meeting agendas; Almirall restructures its European business and buys U.S. dermatology business; biosimilar biologics companies, Almotech and Samsung Bioepis, target Europe.
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products